What's new

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Mar 17, 2025 - 16:54
 0
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Read More

Tags:

Previous Article

Orca Bio to seek approval of T cell transplant after positive trial data

Next Article

Quest Nutrition debuts high-protein shake

Related Posts

Human medicines European public assessment report (EPAR): MicardisPlus, Date of authorisation: 19/04/2002, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 26, 2025  0

DARWIN EU data partners onboarded in phases I, II and III

Feb 20, 2025  0

Training on human variations web-based electronic application form (eAF) functionalities for non-CAPs variations, Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 February 2025, 10:30 (CET) to 11 February 2025, 12:30 (CET)

Training on human variations web-based electronic appli...

Feb 9, 2025  0